ALHC vs. ARGX: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and ARGX, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ARGX towers over ALHC with a market cap of 35.72 billion USD, roughly 11.78 times the 3.03 billion USD of its peer.
ALHC rides a wilder wave with a beta of 1.33, hinting at bigger swings than ARGX’s steadier 0.17.
Quick note: ARGX sports an ADR tag, marking it as a foreign player on U.S. exchanges, unlike the homegrown ALHC.
| Symbol | ALHC | ARGX |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | argenx SE |
| Country | US | NL |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Biotechnology |
| CEO | Mr. John E. Kao | Mr. Timothy Van Hauwermeiren EMBA, M.Sc. |
| Price | 15.33 USD | 584.95 USD |
| Market Cap | 3.03 billion USD | 35.72 billion USD |
| Beta | 1.327 | 0.17 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | March 26, 2021 | May 18, 2017 |
| ADR | No | Yes |
Performance Comparison
This chart compares the performance of ALHC and ARGX over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and ARGX based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALHC has a negative P/E of -32.75, indicating it’s been unprofitable over the past year with no net earnings to support its stock price. On the other hand, ARGX at 51.21 has maintained positive earnings, showing a healthier profit profile.
- ALHC carries a negative Forward PEG of -1.11, hinting at analyst expectations of losses or shrinking earnings in the coming period—a potential warning for its future performance. On the flip side, ARGX at 1.36 sidesteps this concern with a more favorable outlook.
- ARGX has a negative Price-to-Free Cash Flow of -457.12, indicating it’s spent more cash than it’s brought in over the past year—a cash flow shortfall that raises questions about its operational sustainability. Meanwhile, ALHC at 159.00 maintains a positive cash position.
| Symbol | ALHC | ARGX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | 51.21 |
| Forward PEG Ratio (TTM) | -1.11 | 1.36 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 16.54 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 7.77 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | -457.12 |
| EV-to-EBITDA (TTM) | -64.47 | 4584.81 |
| EV-to-Sales (TTM) | 0.86 | 15.88 |
| EV-to-Free Cash Flow (TTM) | 136.01 | -438.95 |
Dividend Comparison
Neither ALHC nor ARGX pays dividends, suggesting both reinvest all profits into growth—likely expansion or innovation—favoring long-term value over immediate income.
| Symbol | ALHC | ARGX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and ARGX, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALHC at -2.98 and ARGX at -20.85 both scrape by with interest coverage under 1.5. Earnings are stretched thin against interest bills, leaving little wiggle room if profits drop.
| Symbol | ALHC | ARGX |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 7.29 |
| Quick Ratio (TTM) | 1.69 | 6.68 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 0.01 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.01 |
| Interest Coverage Ratio (TTM) | -2.98 | -20.85 |